Macrophage migration inhibitory factor downregulation: A novel mechanism of resistance to anti-angiogenic therapy

Oncogene

Volumn 36, Issue 26, 2017, Pages 3749-3759

  Castro, B A ^a   Flanigan, P ^a   Jahangiri, A ^a   Hoffman, D ^a   Chen, W ^a   Kuang, R ^a   De Lay, M ^a   Yagnik, G ^a   Wagner, J R ^a   Mascharak, S ^a   Sidorov, M ^a   Shrivastav, S ^a   Kohanbash, G ^a   Okada, H ^a   Aghi, M K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE 1; BEVACIZUMAB; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CX3CR1; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE B; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; MACROPHAGE MIGRATION INHIBITION FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC THERAPY; ARTICLE; BLOOD BRAIN BARRIER; BONE MARROW DERIVED MACROPHAGE; CANCER GROWTH; CANCER RESISTANCE; CELL PROLIFERATION; CHEMOTAXIS ASSAY; CONDITIONED MEDIUM; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MICROARRAY ANALYSIS; MICROGLIA; MONOCYTE; MOUSE; NONHUMAN; PHENOTYPE; POLARIZATION; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BRAIN NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; MACROPHAGE; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; NUDE MOUSE; TUMOR CELL LINE; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; BEVACIZUMAB; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GLIOBLASTOMA; HUMANS; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MACROPHAGES; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85013188788     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2017.1     Document Type: Article

References (53)

1. Clark AJ, Lamborn KR, Butowski NA, Chang SM, Prados MD, Clarke JL et al. Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment. Neurosurgery 2012; 70: 361-370.
2. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8: 592-603.
3. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I et al. Phase II trial of singleagent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009; 27: 740-745.
4. DeLay M, Jahangiri A, Carbonell WS, Hu YL, Tsao S, Tom MW et al. Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy. Clin Cancer Res 2012; 18: 2930-2942.
5. Piao Y, Liang J, Holmes L, Zurita AJ, Henry V, Heymach JV et al. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. Neuro Oncol 2012; 14: 1379-1392.
6. Gabrusiewicz K, Liu D, Cortes-Santiago N, Hossain MB, Conrad CA, Aldape KD et al. Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes. Oncotarget 2014; 5: 2208-2220.
7. Lu-Emerson C, Snuderl M, Kirkpatrick ND, Goveia J, Davidson C, Huang Y et al. Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. Neuro Oncol 2013; 15: 1079-1087.
8. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004; 25: 677-686.
9. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000prime Reports 2014; 6: 13.
10. Wei J, Gabrusiewicz K, Heimberger A. The controversial role of microglia in malignant gliomas. Clin Dev Immunol 2013; 2013: 285246.
11. Ito D, Imai Y, Ohsawa K, Nakajima K, Fukuuchi Y, Kohsaka S. Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain Res Mol Brain Res 1998; 57: 1-9.
12. Mizutani M, Pino PA, Saederup N, Charo IF, Ransohoff RM, Cardona AE. The fractalkine receptor but not CCR2 is present on microglia from embryonic development throughout adulthood. J Immunol 2012; 188: 29-36.
13. Saederup N, Cardona AE, Croft K, Mizutani M, Cotleur AC, Tsou CL et al. Selective chemokine receptor usage by central nervous system myeloid cells in CCR2-red fluorescent protein knock-in mice. PloS one 2010; 5: e13693.
14. Jahangiri A, De Lay M, Miller LM, Carbonell WS, Hu YL, Lu K et al. Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Clinical Cancer Research 2013; 19: 1773-1783.
15. Carbonell WS, DeLay M, Jahangiri A, Park CC, Aghi MK. beta1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumabresistant glioblastoma. Cancer Res 2013; 73: 3145-3154.
16. Bennett ML, Bennett FC, Liddelow SA, Ajami B, Zamanian JL, Fernhoff NB et al. New tools for studying microglia in the mouse and human CNS. Proc Natl Acad Sci USA 2016; 113: E1738-E1746.
17. Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 2000; 6: 3282-3289.
18. Yaddanapudi K, Putty K, Rendon BE, Lamont GJ, Faughn JD, Satoskar A et al. Control of tumor-associated macrophage alternative activation by macrophage migration inhibitory factor. J Immunol 2013; 190: 2984-2993.
19. Hoppstadter J, Seif M, Dembek A, Cavelius C, Huwer H, Kraegeloh A et al. M2 polarization enhances silica nanoparticle uptake by macrophages. Front Pharmacol 2015; 6: 55.
20. Leidi M, Gotti E, Bologna L, Miranda E, Rimoldi M, Sica A et al. M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. J Immunol 2009; 182: 4415-4422.
21. Choudhary S, Hegde P, Pruitt JR, Sielecki TM, Choudhary D, Scarpato K et al. Macrophage migratory inhibitory factor promotes bladder cancer progression via increasing proliferation and angiogenesis. Carcinogenesis 2013; 34: 2891-2899.
22. Gupta Y, Pasupuleti V, Du W, Welford SM. Macrophage migration inhibitory factor secretion is induced by ionizing radiation and oxidative stress in cancer cells. PloS One 2016; 11: e0146482.
23. Li Z, Ren Y, Wu QC, Lin SX, Liang YJ, Liang HZ. Macrophage migration inhibitory factor enhances neoplastic cell invasion by inducing the expression of matrix metalloproteinase 9 and interleukin-8 in nasopharyngeal carcinoma cell lines. Chin Med J 2004; 117: 107-114.
24. Meyer-Siegler KL, Iczkowski KA, Leng L, Bucala R, Vera PL. Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells. J Immunol 2006; 177: 8730-8739.
25. Piette C, Deprez M, Roger T, Noël A, Foidart J-M, Munaut C. The dexamethasoneinduced inhibition of proliferation, migration, and invasion in glioma cell lines is antagonized by macrophage migration inhibitory factor (MIF) and can be enhanced by specific MIF inhibitors. J Biol Chem 2009; 284: 32483-32492.
26. Sun B, Nishihira J, Yoshiki T, Kondo M, Sato Y, Sasaki F et al. Macrophage migration inhibitory factor promotes tumor invasion and metastasis via the Rho-dependent pathway. Clin Cancer Res 2005; 11: 1050-1058.
27. Hu YL, Jahangiri A, De Lay M, Aghi MK. Hypoxia-induced tumor cell autophagy mediates resistance to anti-angiogenic therapy. Autophagy 2012; 8: 979-981.
28. Muller YA, Chen Y, Christinger HW, Li B, Cunningham BC, Lowman HB et al. VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface. Structure 1998; 6: 1153-1167.
29. Jenkins SJ, Ruckerl D, Cook PC, Jones LH, Finkelman FD, van Rooijen N et al. Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Science 2011; 332: 1284-1288.
30. Redente EF, Higgins DM, Dwyer-Nield LD, Orme IM, Gonzalez-Juarrero M, Malkinson AM. Differential polarization of alveolar macrophages and bone marrow-derived monocytes following chemically and pathogen-induced chronic lung inflammation. J Leukocyte Biol 2010; 88: 159-168.
31. Stoger JL, Gijbels MJ, van der Velden S, Manca M, van der Loos CM, Biessen EA et al. Distribution of macrophage polarization markers in human atherosclerosis. Atherosclerosis 2012; 225: 461-468.
32. Casazza A, Laoui D, Wenes M, Rizzolio S, Bassani N, Mambretti M et al. Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. Cancer Cell 2013; 24: 695-709.
33. Mittelbronn M, Platten M, Zeiner P, Dombrowski Y, Frank B, Zachskorn C et al. Macrophage migration inhibitory factor (MIF) expression in human malignant gliomas contributes to immune escape and tumour progression. Acta Neuropathol 2011; 122: 353-365.
34. Verschuren L, Kooistra T, Bernhagen J, Voshol PJ, Ouwens DM, van Erk M et al. MIF deficiency reduces chronic inflammation in white adipose tissue and impairs the development of insulin resistance, glucose intolerance, and associated atherosclerotic disease. Circ Res 2009; 105: 99-107.
35. Zeiner PS, Preusse C, Blank AE, Zachskorn C, Baumgarten P, Caspary L et al. MIF Receptor CD74 is Restricted to Microglia/Macrophages, Associated with a M1-Polarized Immune Milieu and Prolonged Patient Survival in Gliomas. Brain Pathol 2015; 25: 491-504.
36. Ghoochani A, Schwarz MA, Yakubov E, Engelhorn T, Doerfler A, Buchfelder M et al. MIF-CD74 signaling impedes microglial M1 polarization and facilitates brain tumorigenesis. Oncogene 2016; 35: 6246-6261.
37. Girard E, Strathdee C, Trueblood E, Queva C. Macrophage migration inhibitory factor produced by the tumour stroma but not by tumour cells regulates angiogenesis in the B16-F10 melanoma model. Br J Cancer 2012; 107: 1498-1505.
38. Wang X, Chen T, Leng L, Fan J, Cao K, Duan Z et al. MIF produced by bone marrow-derived macrophages contributes to teratoma progression after embryonic stem cell transplantation. Cancer Res 2012; 72: 2867-2878.
39. Lu KV, Chang JP, Parachoniak CA, Pandika MM, Aghi MK, Meyronet D et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer cell 2012; 22: 21-35.
40. de Groot JF. High-dose antiangiogenic therapy for glioblastoma: less may be more Clin Cancer Res 2011; 17: 6109-6111.
41. Thiele M, Kerschbaumer RJ, Tam FW, Volkel D, Douillard P, Schinagl A et al. Selective targeting of a disease-related conformational isoform of macrophage migration inhibitory factor ameliorates inflammatory conditions. J Immunol 2015; 195, 2343-2352.
42. Rubenstein JL, Kim J, Ozawa T, Zhang M, Westphal M, Deen DF et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000; 2: 306-314.
43. Frentzas S, Simoneau E, Bridgeman VL, Vermeulen PB, Foo S, Kostaras E et al. Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases. Nat Med 2016; 22: 1294-1302.
44. Piao Y, Park SY, Henry V, Smith BD, Tiao N, Flynn DL et al. Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumabresistant glioblastoma mouse models. Neuro Oncol 2016; 18: 1230-1241.
45. Rahbari NN, Kedrin D, Incio J, Liu H, Ho WW, Nia HT et al. Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases. Sci Transl Med 2016; 8: 360ra135.
46. Scholz A, Harter PN, Cremer S, Yalcin BH, Gurnik S, Yamaji M et al. Endothelial cellderived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma. EMBO Mol Med 2015; 8: 39-57.
47. Li JL, Sainson RC, Oon CE, Turley H, Leek R, Sheldon H et al. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res 2011; 71: 6073-6083.
48. Kessler T, Sahm F, Blaes J, Osswald M, Rubmann P, Milford D et al. Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma. Oncotarget 2015; 6: 31050-31068.
49. Cho HR, Hong B, Kim H, Park CK, Park SH, Park S et al. Assessment of bevacizumab resistance increased by expression of BCAT1 in IDH1 wild-type glioblastoma: Application of DSC perfusion MR imaging. Oncotarget 2016; 7: 69606-69615.
50. Piao Y, Liang J, Holmes L, Henry V, Sulman E, de Groot JF. Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition. Clin Cancer Res 2013; 19: 4392-4403.
51. Mao XG, Wang C, Liu DY, Zhang X, Wang L, Yan M et al. Hypoxia upregulates HIG2 expression and contributes to bevacizumab resistance in glioblastoma. Oncotarget 2016; 7: 47808-47820.
52. Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 2014; 2: 632-642.
53. Moughon DL, He H, Schokrpur S, Jiang ZK, Yaqoob M, David J et al. Macrophage blockade using CSF1R inhibitors reverses the vascular leakage underlying malignant ascites in late-stage epithelial ovarian cancer. Cancer Res 2015; 75: 4742-4752.